Enalkiren (BioDeep_00000006506)

   


代谢物信息卡片


3-amino-N-[(2S)-1-[[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-methylbutanamide

化学式: C35H56N6O6 (656.4261116)
中文名称: 依那吉仑
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)CC(C(C(CC1CCCCC1)NC(=O)C(CC2=CN=CN2)NC(=O)C(CC3=CC=C(C=C3)OC)NC(=O)CC(C)(C)N)O)O
InChI: InChI=1S/C35H56N6O6/c1-22(2)15-30(42)32(44)27(16-23-9-7-6-8-10-23)40-34(46)29(18-25-20-37-21-38-25)41-33(45)28(39-31(43)19-35(3,4)36)17-24-11-13-26(47-5)14-12-24/h11-14,20-23,27-30,32,42,44H,6-10,15-19,36H2,1-5H3,(H,37,38)(H,39,43)(H,40,46)(H,41,45)

描述信息

C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors

同义名列表

4 个代谢物同义名

3-amino-N-[(2S)-1-[[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-methylbutanamide; Enalkiren; A 64662; Abbott 64662; A 64662



数据库引用编号

13 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • M Jadhav, C Yeola, G Zope, A Nabar. Aliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its development. Journal of postgraduate medicine. 2012 Jan; 58(1):32-8. doi: 10.4103/0022-3859.93250. [PMID: 22387646]
  • Eduardo Pimenta, Suzanne Oparil. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Vascular health and risk management. 2009; 5(1):453-63. doi: 10.2147/vhrm.s4291. [PMID: 19475781]
  • J Duan, J Jaramillo, G L Jung, A L McLeod, B H Fernandes. A novel renal hypertensive guinea pig model for comparing different inhibitors of the renin-angiotensin system. Journal of pharmacological and toxicological methods. 1996 Apr; 35(2):83-9. doi: 10.1016/1056-8719(96)00004-4. [PMID: 8729434]
  • G A Rongen, J W Lenders, P Smits, T Thien. Clinical pharmacokinetics and efficacy of renin inhibitors. Clinical pharmacokinetics. 1995 Jul; 29(1):6-14. doi: 10.2165/00003088-199529010-00002. [PMID: 7586899]
  • N D Fisher, D R Allan, C L Gaboury, N K Hollenberg. Intrarenal angiotensin II formation in humans. Evidence from renin inhibition. Hypertension (Dallas, Tex. : 1979). 1995 May; 25(5):935-9. doi: 10.1161/01.hyp.25.5.935. [PMID: 7737730]
  • B Jackson, G Liu, R B Perich, D Paxton, L McNicols, G Gutteridge, C I Johnston. Haemodynamic, renal and hormonal responses to enalkiren in four patients with post-surgical oliguria. Clinical and experimental pharmacology & physiology. 1994 Feb; 21(2):163-6. doi: 10.1111/j.1440-1681.1994.tb02488.x. [PMID: 8039272]
  • N D Fisher, D Allan, I Kifor, C L Gaboury, G H Williams, T J Moore, N K Hollenberg. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. Hypertension (Dallas, Tex. : 1979). 1994 Jan; 23(1):44-51. doi: 10.1161/01.hyp.23.1.44. [PMID: 8282330]
  • J P Clozel, W Fischli. Comparative effects of three different potent renin inhibitors in primates. Hypertension (Dallas, Tex. : 1979). 1993 Jul; 22(1):9-17. doi: 10.1161/01.hyp.22.1.9. [PMID: 8319997]
  • S K Gupta, G R Granneman, M Packer, R S Boger. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failure. Journal of cardiovascular pharmacology. 1993 May; 21(5):834-40. doi: 10.1097/00005344-199305000-00022. [PMID: 7685457]
  • S H Rosenberg, K P Spina, K W Woods, J Polakowski, D L Martin, Z Yao, H H Stein, J Cohen, J L Barlow, D A Egan. Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides. Journal of medicinal chemistry. 1993 Feb; 36(4):449-59. doi: 10.1021/jm00056a005. [PMID: 8474101]
  • F H Derkx, J Deinum, M Lipovski, M Verhaar, W Fischli, M A Schalekamp. Nonproteolytic 'activation' of prorenin by active site-directed renin inhibitors as demonstrated by renin-specific monoclonal antibody. The Journal of biological chemistry. 1992 Nov; 267(32):22837-42. doi: 10.1016/s0021-9258(18)50023-5. [PMID: 1429632]
  • B D Dayton, H H Stein, J Cohen, W R Baker, S A Boyd, S L Condon, B G Donner, A K Fung, J R Luly, S H Rosenberg. Effects of angiotensinase inhibitors on plasma protein binding and IC50 determinations of renin inhibitors. Clinical chemistry. 1992 Nov; 38(11):2239-43. doi: . [PMID: 1330373]
  • S K Gupta, G R Granneman, R S Boger, N K Hollenberg, R R Luther. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor). I: Single dose study. Drug metabolism and disposition: the biological fate of chemicals. 1992 Nov; 20(6):821-5. doi: . [PMID: 1362933]
  • S A Boyd, A K Fung, W R Baker, R A Mantei, Y L Armiger, H H Stein, J Cohen, D A Egan, J L Barlow, V Klinghofer. C-terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties. Journal of medicinal chemistry. 1992 May; 35(10):1735-46. doi: 10.1021/jm00088a007. [PMID: 1588555]
  • J M Neutel, R R Luther, R S Boger, M A Weber. Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat. American heart journal. 1991 Oct; 122(4 Pt 1):1094-100. doi: 10.1016/0002-8703(91)90477-y. [PMID: 1656720]
  • R R Luther, H N Glassman, R S Boger. Renin inhibitors in hypertension. Clinical nephrology. 1991 Oct; 36(4):181-6. doi: . [PMID: 1959244]
  • P Cordero, N D Fisher, T J Moore, R Gleason, G H Williams, N K Hollenberg. Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans. Hypertension (Dallas, Tex. : 1979). 1991 Apr; 17(4):510-6. doi: 10.1161/01.hyp.17.4.510. [PMID: 2013477]
  • G W Neuberg, M L Kukin, J Penn, N Medina, M Yushak, M Packer. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. The American journal of cardiology. 1991 Jan; 67(1):63-6. doi: 10.1016/0002-9149(91)90101-p. [PMID: 1986506]
  • P W Anderson, Y S Do, M Schambelan, R Horton, R S Boger, R R Luther, W A Hsueh. Effects of renin inhibition in systemic hypertension. The American journal of cardiology. 1990 Dec; 66(19):1342-7. doi: 10.1016/0002-9149(90)91165-3. [PMID: 2244565]
  • R S Boger, H N Glassman, J H Cavanaugh, P J Schmitz, J Lamm, D Moyse, A Cohen, H D Kleinert, R R Luther. Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension. Hypertension (Dallas, Tex. : 1979). 1990 Jun; 15(6 Pt 2):835-40. doi: 10.1161/01.hyp.15.6.835. [PMID: 2190927]
  • M A Weber, J M Neutel, I Essinger, H N Glassman, R S Boger, R Luther. Assessment of renin dependency of hypertension with a dipeptide renin inhibitor. Circulation. 1990 Jun; 81(6):1768-74. doi: 10.1161/01.cir.81.6.1768. [PMID: 2188754]
  • M Bursztyn, I Gavras, C P Tifft, R Luther, R Boger, H Gavras. Effects of a novel renin inhibitor in patients with essential hypertension. Journal of cardiovascular pharmacology. 1990 Mar; 15(3):493-500. doi: 10.1097/00005344-199003000-00021. [PMID: 1691375]
  • K M Verburg, H D Kleinert, M A Chekal, J R Kadam, G A Young. Renal hemodynamic and excretory responses to renin inhibition induced by A-64662. The Journal of pharmacology and experimental therapeutics. 1990 Feb; 252(2):449-55. doi: . [PMID: 2179529]
  • H N Glassman, H D Kleinert, R S Boger, D M Moyse, A N Griffiths, R R Luther. Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor. Journal of cardiovascular pharmacology. 1990; 16 Suppl 4(?):S76-81. doi: 10.1097/00005344-199016004-00016. [PMID: 1705633]
  • M Bursztyn, I Gavras, C P Tifft, J H Bauer, J C Melby, H Gavras. Renin inhibition with A-64662: effect on blood pressure and hormonal response in man. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 1989 Dec; 7(6):S306-7. doi: 10.1097/00004872-198900076-00149. [PMID: 2698944]
  • A Delabays, J Nussberger, M Porchet, B Waeber, P Hoyos, R Boger, H Glassman, H D Kleinert, R Luther, H R Brunner. Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension (Dallas, Tex. : 1979). 1989 Jun; 13(6 Pt 2):941-7. doi: 10.1161/01.hyp.13.6.941. [PMID: 2661434]
  • J Nussberger, B Waeber, H R Brunner. Angiotensin converting enzyme inhibition and renin inhibition. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 1989 Apr; 7(2):S75-9. doi: 10.1097/00004872-198904002-00016. [PMID: 2666618]
  • K M Verburg, H D Kleinert, J R Kadam, M A Chekal, P F Mento, B M Wilkes. Effects of chronic infusion of renin inhibitor A-64662 in sodium-depleted monkeys. Hypertension (Dallas, Tex. : 1979). 1989 Mar; 13(3):262-72. doi: 10.1161/01.hyp.13.3.262. [PMID: 2646217]
  • H D Kleinert, D Martin, M A Chekal, J Kadam, J R Luly, J J Plattner, T J Perun, R R Luther. Effects of the renin inhibitor A-64662 in monkeys and rats with varying baseline plasma renin activity. Hypertension (Dallas, Tex. : 1979). 1988 Jun; 11(6 Pt 2):613-9. doi: 10.1161/01.hyp.11.6.613. [PMID: 3292414]